Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Public Storage (PSA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Public StorageTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Public Storage vs Regeneron Pharmaceuticals Inc — how do they compare? Public Storage trades at $311.4 (market cap $54.39B), while Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Public Storage pays the higher dividend (3.87%). Which is the better fit depends on your goals.

PSAREGN
Market Cap
$54.39B$70.79B
Sector
Real EstateHealth
52-Week High
$329.64$812.27
52-Week Low
$258.44$545.46
Enterprise Value
$68.63B$64.74B
Dividend Yield
3.87%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Public Storage

Public Storage (PSA) trades at $309.75, down 2.61% on the day, with a bearish technical signal but strong fundamentals including a 39.16% net income margin and consistent earnings beats. Recent developments include the pending acquisition of National Storage Affiliates and a $3.00 dividend payment scheduled for June 30, 2026. The stock is near its 52-week high of $331.00, reflecting investor confidence in its growth trajectory and sector leadership.

The outlook remains positive due to robust profitability, strategic expansions into Canada, and analyst consensus pointing to a $332.25 price target. Key risks include integration challenges from acquisitions and interest rate sensitivity. With 65.72% of analysts rating it Hold, the stock offers steady income potential but requires monitoring of execution risks and market volatility.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Public Storage

Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.

Read more on PSA

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN